Pfizer: bladder cancer treatment meets primary endpoint
(CercleFinance.com) - Pfizer said on Monday that an immunotherapy drug developed in collaboration with Germany's Merck has met the main goal of a late-stage study in patients with locally advanced or metastatic urothelial carcinoma.
The Phase III study met its primary endpoint of overall survival, showing a statistically significant improvement in each of the co-primary populations, the drugmaker said.
Urothelial carcinoma represents about 90% of all bladder cancers. When bladder cancer is metastatic, the five-year survival rate is just 5%.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
The Phase III study met its primary endpoint of overall survival, showing a statistically significant improvement in each of the co-primary populations, the drugmaker said.
Urothelial carcinoma represents about 90% of all bladder cancers. When bladder cancer is metastatic, the five-year survival rate is just 5%.
Copyright (c) 2020 CercleFinance.com. All rights reserved.